Acute hepatitis B virus infection with delayed appearance of hepatitis B core antibody in an immunocompromised patient: a case report

Brousseau, Nicholas; Murphy, Donald G.; Gîlca, Vladimir; Larouche, Jacynthe; Mandal, Sema; Tedder, Richard S.

doi:10.1186/s13256-017-1264-9

Cited by 9 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Delayed or completely absent seroconversion in immunocompromised COVID-19 patients has been previously reported [ 11 ]. Delayed antibody responses to other virus-borne diseases such as Hepatitis B and West Nile has been shown in immunosuppressed patients [ 13 , 14 ]. Samples from these patients who were RT-PCR positive but IgG negative can be attributed to low levels of antibody production that were below the detection limits of the Architect™ and Panbio™ assays.…”

Section: Discussionmentioning

confidence: 99%

A comparative evaluation between the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG assay

Batra¹,

Olivieri²,

Rubin³

et al. 2020

Journal of Clinical Virology

View full text Add to dashboard Cite

Introduction Antibodies to SARS-CoV-2 serve as critical diagnostic markers for determining how broadly the COVID-19 pandemic has spread, confirming patient recovery, monitoring potential long-term effects of infection, and evaluating potential protection from reinfection. As new antibody tests become available, it is important to evaluate their performance and utility. The aim of this study was to compare the performance of the Abbott Panbio TM COVID-19 IgG/IgM Rapid Test Device against the Abbott Architect TM SARS CoV-2 IgG Assay for the detection of the COVID-19 IgG antibody. Methods Two panels of specimens were utilized to challenge both antibody tests: (1) a set of 150 prepandemic negative specimens collected in 2014, and (2) a set of 122 specimens from 87 hospitalized COVID-19 patients in the US and UK that were confirmed with a positive SARS-CoV-2 RNA test result. Results The Architect TM test had a specificity of 100 % and sensitivity of 99.1 % and 93.9 % when excluding or including immunocompromised patients, respectively for specimens collected >14 days post symptom onset or >5 days post-RNA testing. The Panbio TM test had 99.3 % agreement to Architect TM . Notably, N = 6 immune-compromised individuals were identified that did not develop detectable antibodies by day 30. Conclusion There is good concordance between the Architect TM SARS CoV-2 IgG Assay and Panbio TM COVID-19 IgG/IgM Rapid Test Device for the detection of SARS CoV-2 IgG.

show abstract

Section: Discussionmentioning

confidence: 99%

A comparative evaluation between the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG assay

Batra¹,

Olivieri²,

Rubin³

et al. 2020

Journal of Clinical Virology

View full text Add to dashboard Cite

show abstract

“…That patient developed anti-HBc 6 months after first positive HBsAg, with the delay attributed to immunosuppression due to Rituximab. Both Avettand-Fenoel et al and Brousseu et al showed that patients developed HBc antibodies once immunosuppression was less pronounced or after chemotherapy completion (16,17), further establishing the role of immune suppression in lack of anti-HBc response in acute HBV infection.…”

Section: Discussionmentioning

confidence: 94%

“…The patients in the study were immunosuppressed due to HIV infection, solid organ transplant (kidney, heart, or bone marrow), while 1 patient had HCV co-infection. More recently, Brousseu et al reported a case of acute HBV infection in a patient receiving rituximab for low-grade non-Hodgkin lymphoma with isolated HBsAg positivity (17).…”

Section: Discussionmentioning

confidence: 99%

De novo hepatitis B surface antigen (HBsAg)-positive, core antibody (anti-HBc)-negative, hepatitis B virus infection post-liver transplant from an anti-HBc, HBsAg-negative donor

Yoshida¹

2021

Hepatology Forum

View full text Add to dashboard Cite

Liver transplant donors and recipients are routinely screened for Hepatitis B virus (HBV) infection with Hepatitis B surface antigen (HBsAg) and Hepatitis B core antibody (anti-HBc).Organs are accepted from donors who are HBV negative, with the caveat of increased monitoring when accepting organs from 'increased risk donors'. Transplant recipients are vaccinated if there is no sign of previous infection or immunity and monitored for reactivation in case of previous HBV infection. In cases where both the donor and recipient are HBV negative, no antiviral prophylaxis is used post-transplant. We present a case of a HBV immunized, anti-HBc negative patient who underwent orthotopic liver transplant from an anti-HBc negative donor. The patient did not receive post-transplant antiviral prophylaxis because of mutual anti-HBc-seronegative status. However, she developed HBV infection with isolated HBsAg, and persistently negative anti-HBc. Mutations in the core/pre-core regions of HBV gene were not implicated for the unique serology in this case. Immunosuppression post-liver transplant is the likely etiology for isolated HBsAg seroconversion despite significantly elevated HBV DNA. Our experience suggests that HBV DNA screening of liver transplant donors and recipients, in addition to HBV DNA monitoring in recipients, may reduce transplant-associated HBV risk.

show abstract

“…Indeed, we had few subjects with profound immunosuppression who were still negative 15 days after onset. We know, however, that seroconversion could occur later in such patients [ 18 , 19 ]. Future studies should focus on seroconversion from Day 15 to Day 30 in highly immunocompromised patients infected with COVID-19.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of performance of two SARS-CoV-2 Rapid IgM-IgG combined antibody tests on capillary whole blood samples from the fingertip

et al. 2020

View full text Add to dashboard Cite

Background The SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus 2) is responsible for the infectious respiratory disease called COVID-19 (COronaVIrus Disease 2019). In response to the growing COVID-19 pandemic, point-of-care (POC) tests have been developed to detect specific antibodies, IgG and IgM, to SARS-CoV-2 virus in human whole blood. We conducted a prospective observational study to evaluate the performance of two POC tests, COVID-PRESTO ® and COVID-DUO ® , compared to the gold standard, RT-PCR (real-time reverse transcriptase polymerase chain reaction). Methods RT-PCR testing of SARS-Cov-2 was performed from nasopharyngeal swab specimens collected in adult patients visiting the infectious disease department at the hospital (Orléans, France). Capillary whole blood (CWB) samples from the fingertip taken at different time points after onset of the disease were tested with POC tests. The specificity and sensitivity of the rapid test kits compared to test of reference (RT-PCR) were calculated. Results Among 381 patients with symptoms of COVID-19 who went to the hospital for a diagnostic, 143 patients were RT-PCR negative. Results of test with POC tests were all negative for these patients, indicating a specificity of 100% for both POC tests. In the RT-PCR positive subgroup (n = 238), 133 patients were tested with COVID-PRESTO ® and 129 patients were tested with COVID-DUO ® (24 patients tested with both). The further the onset of symptoms was from the date of collection, the greater the sensitivity. The sensitivity of COVID-PRESTO ® test ranged from 10.00% for patients having experienced their 1 st symptoms from 0 to 5 days ago to 100% in patients where symptoms had occurred more than 15 days before the date of tests. For COVID-DUO ® test, the sensitivity ranged from 35.71% [0–5 days] to 100% (> 15 days). Conclusion COVID-PRESTO ® and DUO ® POC tests turned out to be very specific (none false positive) and to be sensitive enough after 15 days from onset of symptom. These easy to use IgG/IgM combined test kits are the first ones allowing a screening with CWB sample, by typing from a finger prick. These rapid tests are particularly interesting for screening in low resource settings.

show abstract

Acute hepatitis B virus infection with delayed appearance of hepatitis B core antibody in an immunocompromised patient: a case report

Cited by 9 publications

References 13 publications

A comparative evaluation between the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG assay

A comparative evaluation between the Abbott Panbio™ COVID-19 IgG/IgM rapid test device and Abbott Architect™ SARS CoV-2 IgG assay

De novo hepatitis B surface antigen (HBsAg)-positive, core antibody (anti-HBc)-negative, hepatitis B virus infection post-liver transplant from an anti-HBc, HBsAg-negative donor

Evaluation of performance of two SARS-CoV-2 Rapid IgM-IgG combined antibody tests on capillary whole blood samples from the fingertip

Contact Info

Product

Resources

About